Metolar Trio 50 Tablet ER is a combination antihypertensive medication containing Cilnidipine (10 mg), Metoprolol Succinate (50 mg), and Telmisartan (40 mg). This extended-release formulation is designed to provide effective and sustained blood pressure control in patients with essential hypertension. Cilnidipine, a calcium channel blocker, inhibits L-type and N-type calcium channels, leading to vasodilation and reduction of peripheral vascular resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate and myocardial contractility, thereby reducing cardiac output and oxygen demand. Telmisartan, an angiotensin II receptor blocker (ARB), prevents vasoconstriction and aldosterone secretion by selectively blocking the AT1 receptor, contributing to vasodilation and sodium excretion. The synergistic action of these three agents targets multiple pathways involved in hypertension pathophysiology, resulting in enhanced antihypertensive efficacy. Metolar Trio 50 Tablet ER is indicated for patients requiring combination therapy to achieve optimal blood pressure control and reduce the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. It should be used under medical supervision, with dosage adjustments based on individual patient response and tolerance. Common adverse effects may include dizziness, fatigue, and hypotension. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy.

Dosage & How to Use